The adoption of technology has already witnessed a growing momentum lately and in 2024 there will be a wider adoption of such tech for better outcomes.
In 2024, M&A in the pharma and life sciences sector may witness a sound performance with the deal value almost hitting $275 billion, as anticipated by PwC.
Adoption of advanced therapies and working collaboratively can help in maximising the patient access which is a part of driving an innovation-first mindset.
Singapore is leading the way in being the preferred partner across the world because of its prominence of being the centre in entrepreneurship & innovation.
As per the Forbes and Numerof & Associates 2024 Global Pharma Outlook, the worldwide pharma sector is all set to intensify further due to stiff pressures.
